MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, Martin Ellis, Laura Fox, Yeow T Goh, Vikas Gupta, Claire Harrison, Jean-Jacques Kiladjian, Mihaela C Lazaroiu, Adam Mead, Donal McLornan, Mary F McMullin, Stephen T Oh, Andrew Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Vannucchi, Sung-Soo Yoon, Mark M KowalskiRuben A Mesa

Research output: Contribution to journalArticlepeer-review

27 Downloads (Pure)

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Original languageEnglish
JournalFuture oncology (London, England)
Early online date11 Jan 2021
DOIs
Publication statusEarly online date - 11 Jan 2021

Fingerprint Dive into the research topics of 'MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic'. Together they form a unique fingerprint.

Cite this